Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
41.36
-0.30 (-0.72%)
May 13, 2025, 4:00 PM - Market closed
Guardant Health Revenue
Guardant Health had revenue of $203.47M in the quarter ending March 31, 2025, with 20.76% growth. This brings the company's revenue in the last twelve months to $774.00M, up 28.20% year-over-year. In the year 2024, Guardant Health had annual revenue of $739.02M with 31.04% growth.
Revenue (ttm)
$774.00M
Revenue Growth
+28.20%
P/S Ratio
6.59
Revenue / Employee
$382,977
Employees
2,021
Market Cap
5.12B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GH News
- 5 days ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire
- 5 days ago - TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year - Business Wire
- 6 days ago - Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Guardant Health: Tailwinds Are Beginning To Impact The Financials - Seeking Alpha
- 13 days ago - Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance - Business Wire
- 14 days ago - Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types - Business Wire
- 15 days ago - CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer - Business Wire